BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stine JG, Niccum BA, Zimmet AN, Intagliata N, Caldwell SH, Argo CK, Northup PG. Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis. Clin Transl Gastroenterol 2018;9:140. [PMID: 29511162 DOI: 10.1038/s41424-018-0002-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Sigal SH, Sherman Z, Jesudian A. Clinical Implications of Thrombocytopenia for the Cirrhotic Patient. Hepat Med. 2020;12:49-60. [PMID: 32341665 DOI: 10.2147/hmer.s244596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Нетяженко ВЗ, Баженова НМ. The Effect of Obesity on the State of Platelet-plasma Hemostasis in Patients with Essential Hypertension in Combination with Non-alcoholic Fatty Liver Disease. Family Medicine 2020;0:56-62. [DOI: 10.30841/2307-5112.4.2020.217657] [Reference Citation Analysis]
3 Fan X, Huang X, Hershman M, Zheng X, Jiang C, Yue B, Weisberg I. Portal vein thrombosis prevalence and mortality among alcoholic cirrhosis in a nationwide inpatient cohort. Eur J Gastroenterol Hepatol 2020;32:1160-7. [PMID: 31834054 DOI: 10.1097/MEG.0000000000001624] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Sasso R, Rockey DC. Anticoagulation Therapy in Patients with Liver Cirrhosis is Associated With an Increased Risk of Variceal Hemorrhage. The American Journal of Medicine 2019;132:758-66. [DOI: 10.1016/j.amjmed.2019.01.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 von Meijenfeldt FA, Lisman T. Fibrinolysis in Patients with Liver Disease. Semin Thromb Hemost 2021;47:601-9. [PMID: 33772480 DOI: 10.1055/s-0040-1718924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Turco L, de Raucourt E, Valla DC, Villa E. Anticoagulation in the cirrhotic patient. JHEP Rep 2019;1:227-39. [PMID: 32039373 DOI: 10.1016/j.jhepr.2019.02.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
7 Stine JG, Schreibman I, Navabi S, Kang M, Dahmus J, Soriano C, Rivas G, Hummer B, Beyer M, Tressler H, Kimball SR, Patterson AD, Schmitz K, Sciamanna C. Nonalcoholic steatohepatitis Fitness Intervention in Thrombosis (NASHFit): Study protocol for a randomized controlled trial of a supervised aerobic exercise program to reduce elevated clotting risk in patients with NASH. Contemp Clin Trials Commun 2020;18:100560. [PMID: 32309672 DOI: 10.1016/j.conctc.2020.100560] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
8 Molinari M, Fernandez-Carrillo C, Dai D, Dana J, Clemente-Sanchez A, Dharmayan S, Kaltenmeier C, Liu H, Behari J, Rachakonda V, Ganesh S, Hughes C, Tevar A, Al Harakeh H, Emmanuel B, Humar A, Bataller R. Portal vein thrombosis and renal dysfunction: a national comparative study of liver transplant recipients for NAFLD versus alcoholic cirrhosis. Transpl Int 2021;34:1105-22. [PMID: 33780554 DOI: 10.1111/tri.13873] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Vuilleumier PH, Nagler M, Beldi G, Vogt A. Orthotopic Liver Transplant in a Patient Anticoagulated With Rivaroxaban: A Case Report. A A Pract 2019;13:54-7. [PMID: 30829681 DOI: 10.1213/XAA.0000000000000989] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 McSweeney L, Breckons M, Fattakhova G, Oluboyede Y, Vale L, Ternent L, Balp MM, Doward L, Brass CA, Beyer F, Sanyal A, Anstee QM. Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis. JHEP Rep 2020;2:100099. [PMID: 32435754 DOI: 10.1016/j.jhepr.2020.100099] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
11 Ciavarella A, Gnocchi D, Custodero C, Lenato GM, Fiore G, Sabbà C, Mazzocca A. Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease. Thromb Res 2021;198:139-50. [PMID: 33340925 DOI: 10.1016/j.thromres.2020.12.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Virović-Jukić L, Stojsavljević-Shapeski S, Forgač J, Kukla M, Mikolašević I. Non-alcoholic fatty liver disease - a procoagulant condition?Croat Med J. 2021;62:25-33. [PMID: 33660958 DOI: 10.3325/cmj.2021.62.25] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Tana C, Ballestri S, Ricci F, Di Vincenzo A, Ticinesi A, Gallina S, Giamberardino MA, Cipollone F, Sutton R, Vettor R, Fedorowski A, Meschi T. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications. Int J Environ Res Public Health. 2019;16. [PMID: 31455011 DOI: 10.3390/ijerph16173104] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 15.7] [Reference Citation Analysis]
14 Verbeek TA, Stine JG, Saner FH, Bezinover D. Hypercoagulability in End-stage Liver Disease: Review of Epidemiology, Etiology, and Management. Transplant Direct 2018;4:e403. [PMID: 30534594 DOI: 10.1097/TXD.0000000000000843] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 3.3] [Reference Citation Analysis]
15 Simonetto DA, Singal AK, Garcia-Tsao G, Caldwell SH, Ahn J, Kamath PS. ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation. Am J Gastroenterol. 2020;115:18-40. [PMID: 31895720 DOI: 10.14309/ajg.0000000000000486] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 13.0] [Reference Citation Analysis]
16 Hanna K, Khalid A, Hamidi M, Gries L, Haddadin Z, Kulvatunyou N, Zeeshan M, Joseph B. Chronic Alcohol Consumption and Risk of Deep Venous Thrombosis: A Propensity-Matched Analysis. J Surg Res 2019;244:251-6. [PMID: 31301481 DOI: 10.1016/j.jss.2019.06.067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Sharma S, Stine JG, Verbeek T, Bezinover D. Management of Patients With Non-alcoholic Steatohepatitis Undergoing Liver Transplantation: Considerations for the Anesthesiologist. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00601-7. [PMID: 34391652 DOI: 10.1053/j.jvca.2021.07.020] [Reference Citation Analysis]
18 Wen X, Wang S, Taveira TH, Akhlaghi F. Required warfarin dose and time in therapeutic range in patients with diagnosed Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH). PLoS One 2021;16:e0251665. [PMID: 34525124 DOI: 10.1371/journal.pone.0251665] [Reference Citation Analysis]
19 Spinosa M, Stine JG. Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State? Curr Pharm Des 2020;26:1036-44. [PMID: 32003679 DOI: 10.2174/1381612826666200131101553] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
20 Rivas G, Hummer-Bair B, Bezinover D, Kadry Z, Stine J. Plasminogen activator inhibitor is significantly elevated in liver transplant recipients with decompensated NASH cirrhosis. BMJ Open Gastroenterol 2021;8:e000683. [PMID: 34341018 DOI: 10.1136/bmjgast-2021-000683] [Reference Citation Analysis]
21 Ballestri S, Capitelli M, Fontana MC, Arioli D, Romagnoli E, Graziosi C, Lonardo A, Marietta M, Dentali F, Cioni G. Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review. Adv Ther 2020;37:1910-32. [PMID: 32285340 DOI: 10.1007/s12325-020-01307-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
22 Zheng Z, Nakamura K, Gershbaum S, Wang X, Thomas S, Bessler M, Schrope B, Krikhely A, Liu RM, Ozcan L, López JA, Tabas I. Interacting hepatic PAI-1/tPA gene regulatory pathways influence impaired fibrinolysis severity in obesity. J Clin Invest 2020;130:4348-59. [PMID: 32657780 DOI: 10.1172/JCI135919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]